Who owns Edgewise Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of EWTX from SEC Form 13F filings across 254 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 254 institutions disclosed 125.1M shares of Edgewise Therapeutics, Inc. worth $5.08B — about 114.9% of shares outstanding; the largest disclosed holder is ORBIMED ADVISORS LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
254
13F holders
$5.08B
value, 2026 filers
114.9%
of shares outstanding (125.1M sh)
49
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of EWTX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 15.5M | $630.1M | 11.5% | 14.3% | 0.0% |
| 2 | Paradigm Biocapital Advisors LP | 10.8M | $437.6M | 8.7% | 9.9% | +5.5% |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 8.4M | $340.7M | 3.4% | 7.7% | 0.0% |
| 4 | Janus Henderson Group Ltd.NEW | 7.3M | $296.3M | 0.1% | 6.7% | new |
| 5 | BlackRock, Inc. | 7.3M | $295.3M | 0.0% | 6.7% | +10.1% |
| 6 | NOVO HOLDINGS A/S | 5.3M | $217.2M | 14.6% | 4.9% | 0.0% |
| 7 | Driehaus Capital Management LLC | 4.4M | $178.7M | 1.2% | 4% | -6.9% |
| 8 | PERCEPTIVE ADVISORS LLC | 4.1M | $168.0M | 2.9% | 3.8% | -5.4% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 3.9M | $159.6M | 0.0% | 3.6% | +1.8% |
| 10 | BAKER BROS. ADVISORS LP | 3.7M | $150.3M | 0.7% | 3.4% | 0.0% |
| 11 | Siren, L.L.C. | 2.8M | $113.8M | 2.7% | 2.6% | -11.9% |
| 12 | BANK OF AMERICA CORP /DE/ | 2.6M | $105.3M | 0.0% | 2.4% | +66.5% |
| 13 | CITADEL ADVISORS LLC | 2.6M | $104.4M | 0.0% | 2.4% | +447.3% |
| 14 | First Light Asset Management, LLC | 2.5M | $100.8M | 6.0% | 2.3% | +126.7% |
| 15 | Integral Health Asset Management, LLC | 2.4M | $97.4M | 5.9% | 2.2% | +20.0% |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 2.3M | $92.7M | 0.0% | 2.1% | +5.0% |
| 17 | BRAIDWELL LP | 2.1M | $84.0M | 3.5% | 1.9% | +3.6% |
| 18 | STATE STREET CORP | 1.9M | $77.1M | 0.0% | 1.7% | +3.9% |
| 19 | Cormorant Asset Management, LP | 1.9M | $75.5M | 5.1% | 1.7% | -25.9% |
| 20 | MORGAN STANLEY | 1.7M | $70.7M | 0.0% | 1.6% | -10.6% |
| 21 | ALLIANCEBERNSTEIN L.P. | 1.7M | $70.3M | 0.0% | 1.6% | -18.2% |
| 22 | MPM BIOIMPACT LLC | 1.6M | $64.0M | 4.7% | 1.4% | -2.8% |
| 23 | MARSHALL WACE, LLP | 1.3M | $51.0M | 0.0% | 1.2% | +20477.5% |
| 24 | Deep Track Capital, LPNEW | 1.1M | $46.6M | 0.8% | 1.1% | new |
| 25 | AMERICAN CENTURY COMPANIES INC | 1.1M | $45.8M | 0.0% | 1% | +0.1% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.